amifostine anhydrous has been researched along with Esophagitis in 24 studies
Amifostine: A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia.
amifostine : An organic thiophosphate that is the S-phospho derivative of 2-[(3-aminopropyl)amino]ethanethiol. A prodrug for the free thiol, WR-1065, which is used as a cytoprotectant in cancer chemotherapy and radiotherapy.
Esophagitis: INFLAMMATION, acute or chronic, of the ESOPHAGUS caused by BACTERIA, chemicals, or TRAUMA.
| Excerpt | Relevance | Reference |
|---|---|---|
| " However, patient self-assessments suggested a possible advantage to AM that is being explored with modified dosing route strategies." | 2.71 | Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: radiation therapy oncology group trial 98-01. ( Axelrod, R; Byhardt, R; Komaki, R; Langer, C; Machtay, M; Movsas, B; Nicolaou, N; Sarna, L; Scott, C; Smith, C; Wasserman, T; Werner-Wasik, M, 2005) |
| "Acute esophagitis was scored weekly." | 2.70 | Phase II: trial of twice weekly amifostine in patients with non-small cell lung cancer treated with chemoradiotherapy. ( Axelrod, RS; Chapman, AE; Curran, WJ; Deshields, M; Friedland, DP; Grubbs, S; Hauck, W; Rose, LJ; Werner-Wasik, M, 2002) |
| "Mucositis is a highly significant, and sometimes dose-limiting, toxicity of cancer therapy." | 2.50 | MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. ( Barasch, A; Bowen, J; Elad, S; Elting, L; Epstein, J; Keefe, DM; Lalla, RV; McGuire, DB; Migliorati, C; Nicolatou-Galitis, O; Peterson, DE; Raber-Durlacher, JE; Sonis, ST, 2014) |
| "radiotherapy plus amifostine for cancer treatment." | 2.43 | Amifostine reduces side effects and improves complete response rate during radiotherapy: results of a meta-analysis. ( Clark, LG; Clark, OA; Sasse, AD; Sasse, EC, 2006) |
| "Mucositis is a significant complication of cancer therapy, with important clinical and economic implications." | 2.43 | Amifostine in the management of radiation-induced and chemo-induced mucositis. ( Bensadoun, RJ; Keefe, D; Lalla, RV; Schubert, MM, 2006) |
| "Radiation-induced esophagitis is a frequent acute side effect in curative and palliative radiotherapy of thoracal and cervical tumors." | 2.40 | Therapy and prophylaxis of acute and late radiation-induced sequelae of the esophagus. ( Feldmann, HJ; Geinitz, H; Zimmermann, FB, 1998) |
| "Esophagitis is a major complication of chemoradiation therapy in patients with non-small cell lung cancer, producing significant morbidity and resulting in treatment interruptions." | 1.33 | Amifostine in chemoradiation therapy for non-small cell lung cancer: review of experience and design of a phase II trial assessing subcutaneous and intravenous bolus administration. ( Langer, C; Movsas, B; Werner-Wasik, M, 2005) |
| "Esophageal cancer is treated optimally with a combined-modality approach according to most clinical investigators." | 1.31 | Esophageal cancer and the esophagus: challenges and potential strategies for selective cytoprotection of the tumor-bearing organ during cancer treatment. ( Jatoi, A; Thomas, CR, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (12.50) | 18.2507 |
| 2000's | 20 (83.33) | 29.6817 |
| 2010's | 1 (4.17) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lalla, RV | 2 |
| Bowen, J | 1 |
| Barasch, A | 1 |
| Elting, L | 1 |
| Epstein, J | 1 |
| Keefe, DM | 1 |
| McGuire, DB | 1 |
| Migliorati, C | 1 |
| Nicolatou-Galitis, O | 1 |
| Peterson, DE | 1 |
| Raber-Durlacher, JE | 1 |
| Sonis, ST | 1 |
| Elad, S | 1 |
| Senzer, N | 2 |
| Leong, SS | 1 |
| Tan, EH | 1 |
| Fong, KW | 1 |
| Wilder-Smith, E | 1 |
| Ong, YK | 1 |
| Tai, BC | 1 |
| Chew, L | 1 |
| Lim, SH | 1 |
| Wee, J | 1 |
| Lee, KM | 1 |
| Foo, KF | 1 |
| Ang, P | 1 |
| Ang, PT | 1 |
| Antonadou, D | 4 |
| Throuvalas, N | 3 |
| Petridis, A | 2 |
| Bolanos, N | 2 |
| Sagriotis, A | 2 |
| Synodinou, M | 3 |
| Choi, NC | 1 |
| Veslemes, M | 1 |
| Mehta, V | 2 |
| Movsas, B | 2 |
| Scott, C | 1 |
| Langer, C | 2 |
| Werner-Wasik, M | 4 |
| Nicolaou, N | 1 |
| Komaki, R | 3 |
| Machtay, M | 1 |
| Smith, C | 1 |
| Axelrod, R | 1 |
| Sarna, L | 1 |
| Wasserman, T | 2 |
| Byhardt, R | 1 |
| Gopal, R | 1 |
| Chang, JY | 1 |
| Wu, X | 1 |
| Allen, PK | 1 |
| Milas, L | 2 |
| Liao, Z | 2 |
| Fossella, FV | 2 |
| Travis, E | 1 |
| Spitz, MR | 1 |
| Wynn, RB | 1 |
| Sasse, AD | 1 |
| Clark, LG | 1 |
| Sasse, EC | 1 |
| Clark, OA | 1 |
| Bensadoun, RJ | 1 |
| Schubert, MM | 1 |
| Keefe, D | 1 |
| Tannehill, SP | 1 |
| Mehta, MP | 2 |
| Larson, M | 1 |
| Storer, B | 1 |
| Pellet, J | 1 |
| Kinsella, TJ | 1 |
| Schiller, JH | 1 |
| Zimmermann, FB | 1 |
| Geinitz, H | 1 |
| Feldmann, HJ | 1 |
| Coliarakis, N | 1 |
| Athanassiou, H | 1 |
| Kouveli, A | 1 |
| Verigos, C | 1 |
| Georgakopoulos, G | 1 |
| Panoussaki, K | 1 |
| Karageorgis, P | 1 |
| Axelrod, RS | 1 |
| Friedland, DP | 1 |
| Hauck, W | 1 |
| Rose, LJ | 1 |
| Chapman, AE | 1 |
| Grubbs, S | 1 |
| Deshields, M | 1 |
| Curran, WJ | 1 |
| Lee, JS | 1 |
| Kaplan, B | 1 |
| Allen, P | 1 |
| Kelly, JF | 1 |
| Stevens, CW | 1 |
| Zinner, R | 1 |
| Papadimitrakopoulou, V | 1 |
| Khuri, F | 1 |
| Glisson, B | 1 |
| Pisters, K | 1 |
| Kurie, J | 1 |
| Herbst, R | 1 |
| Ro, J | 1 |
| Thames, HD | 1 |
| Hong, WK | 1 |
| Cox, JD | 1 |
| Arquette, M | 1 |
| Govindan, R | 1 |
| Garfield, D | 1 |
| Gillenwater, H | 1 |
| Socinski, M | 1 |
| Jatoi, A | 1 |
| Thomas, CR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Study of a New Medical Device for Oral Mucositis (MDOM Trial)[NCT05104268] | Phase 1/Phase 2 | 100 participants (Anticipated) | Interventional | 2021-11-30 | Not yet recruiting | ||
| Low Power Laser Therapy As Prevention Of Oral Mucositis And Oropharyngeal Pain In Patients Undergoing Allogenetic Hematopoietic Stem Cell Transplantation.[NCT06071637] | Phase 3 | 84 participants (Anticipated) | Interventional | 2023-08-01 | Recruiting | ||
| Cryoprotection of Chemotherapy-induced Oral Mucositis After Autologous Stem Cell Transplantation, a Randomized Study[NCT03203733] | 182 participants (Actual) | Interventional | 2017-06-12 | Completed | |||
| A Phase 1/Phase 2 Study for the Prevention of Oral Mucositis (SPOM)[NCT05338398] | Phase 1/Phase 2 | 100 participants (Anticipated) | Interventional | 2022-04-15 | Enrolling by invitation | ||
| Opioid Therapy vs Multimodal Analgesia in Head and Neck Cancer: A Randomized Clinical Trial[NCT04221165] | Phase 2 | 62 participants (Anticipated) | Interventional | 2020-08-04 | Recruiting | ||
| Phase I Study of Multiple Ascending Dose, to Investigate the Safety and Tolerability of the Use of Copaiba in Patients With Oral Cancer Submitted to Radiotherapy[NCT05308732] | Phase 1 | 36 participants (Anticipated) | Interventional | 2021-05-11 | Recruiting | ||
| A Phase III Randomized Study of Amifostine Mucosal Protection for Patients With Favorable Performance Inoperable Stage II-III A/B Non-Small Cell Lung Cancer (NSCLC) Receiving Sequential Induction and Concurrent Hyperfractionated Radiotherapy With Paclitax[NCT00003313] | Phase 3 | 243 participants (Actual) | Interventional | 1998-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
9 reviews available for amifostine anhydrous and Esophagitis
| Article | Year |
|---|---|
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.
Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop | 2014 |
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.
Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop | 2014 |
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.
Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop | 2014 |
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.
Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop | 2014 |
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.
Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop | 2014 |
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.
Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop | 2014 |
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.
Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop | 2014 |
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.
Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop | 2014 |
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.
Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop | 2014 |
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.
Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop | 2014 |
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.
Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop | 2014 |
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.
Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop | 2014 |
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.
Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop | 2014 |
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.
Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop | 2014 |
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.
Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop | 2014 |
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.
Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop | 2014 |
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.
Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop | 2014 |
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.
Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop | 2014 |
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.
Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop | 2014 |
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.
Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop | 2014 |
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.
Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop | 2014 |
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.
Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop | 2014 |
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.
Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop | 2014 |
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.
Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop | 2014 |
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.
Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop | 2014 |
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.
Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop | 2014 |
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.
Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop | 2014 |
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.
Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop | 2014 |
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.
Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop | 2014 |
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.
Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop | 2014 |
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.
Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop | 2014 |
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.
Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop | 2014 |
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.
Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop | 2014 |
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.
Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop | 2014 |
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.
Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop | 2014 |
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.
Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop | 2014 |
Radioprotective effect of amifostine in radiation pneumonitis.
Topics: Amifostine; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic | 2003 |
Open label multicenter trial of subcutaneous amifostine (Ethyol) in the prevention of radiation induced esophagitis and pneumonitis in patients with measurable, unresectable non-small cell lung cancer.
Topics: Amifostine; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; | 2004 |
Pulmonary toxicity associated with the treatment of non-small cell lung cancer and the effects of cytoprotective strategies.
Topics: Amifostine; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Combine | 2005 |
Treatment-related esophagitis.
Topics: Amifostine; Antineoplastic Agents; Dose Fractionation, Radiation; Esophagitis; Humans; Lung Neoplasm | 2005 |
Amifostine reduces side effects and improves complete response rate during radiotherapy: results of a meta-analysis.
Topics: Amifostine; Cystitis; Deglutition Disorders; Esophagitis; Humans; Neoplasms; Radiation Injuries; Rad | 2006 |
Amifostine in the management of radiation-induced and chemo-induced mucositis.
Topics: Amifostine; Antineoplastic Agents; Combined Modality Therapy; Esophagitis; Evidence-Based Medicine; | 2006 |
Protection of normal tissues from the cytotoxic effects of radiation therapy: focus on amifostine.
Topics: Amifostine; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Clinical Trials, Phase II as T | 1998 |
Therapy and prophylaxis of acute and late radiation-induced sequelae of the esophagus.
Topics: Amifostine; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Deglutition Diso | 1998 |
13 trials available for amifostine anhydrous and Esophagitis
| Article | Year |
|---|---|
A phase III randomized evaluation of amifostine in stage IIIA/IIIB non-small cell lung cancer patients receiving concurrent carboplatin, paclitaxel, and radiation therapy followed by gemcitabine and cisplatin intensification: preliminary findings.
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non | 2002 |
Randomized double-blind trial of combined modality treatment with or without amifostine in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non | 2003 |
Effect of amifostine on toxicities associated with radiochemotherapy in patients with locally advanced non-small-cell lung cancer.
Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell L | 2003 |
Amifostine reduces radiochemotherapy-induced toxicities in patients with locally advanced non-small cell lung cancer.
Topics: Aged; Amifostine; Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modal | 2003 |
Open label multicenter trial of subcutaneous amifostine (Ethyol) in the prevention of radiation induced esophagitis and pneumonitis in patients with measurable, unresectable non-small cell lung cancer.
Topics: Amifostine; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; | 2004 |
Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: radiation therapy oncology group trial 98-01.
Topics: Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small- | 2005 |
Mutagen sensitivity may predict lung protection by amifostine for patients with locally advanced non-small cell lung cancer treated by chemoradiotherapy.
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Non-S | 2005 |
Effect of amifostine on toxicities associated with sequential chemotherapy and radiation therapy for unresectable non-small-cell lung cancer: results of a phase II trial.
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell L | 1997 |
Randomized phase III trial of radiation treatment +/- amifostine in patients with advanced-stage lung cancer.
Topics: Acute Disease; Amifostine; Esophagitis; Female; Humans; Lung Neoplasms; Male; Middle Aged; Premedica | 2001 |
Phase II: trial of twice weekly amifostine in patients with non-small cell lung cancer treated with chemoradiotherapy.
Topics: Acute Disease; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcin | 2002 |
Randomized phase III study of chemoradiation with or without amifostine for patients with favorable performance status inoperable stage II-III non-small cell lung cancer: preliminary results.
Topics: Adult; Aged; Amifostine; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Combined | 2002 |
Radiotherapy or chemotherapy followed by radiotherapy with or without amifostine in locally advanced lung cancer.
Topics: Acute Disease; Amifostine; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Combined Modality | 2002 |
Phase II evaluation of amifostine as an esophageal mucosal protectant in the treatment of limited-stage small cell lung cancer with chemotherapy and twice-daily radiation.
Topics: Amifostine; Antineoplastic Agents; Carcinoma, Small Cell; Combined Modality Therapy; Dose-Response R | 2002 |
3 other studies available for amifostine anhydrous and Esophagitis